Cystic fibrosis

Global High Resolution Melting Research Report 2023: Market to Reach $385.6 Billion by 2030 - Clinical Diagnostics be the Fastest-growing Segment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Health, Technology, Other Technology, Other Health, Other Science, Science, Zygosity, COPD, Conditional sentence, Prevalence, Barack Obama, Genomics, Patient, DSM-IV codes, FDA, USD, QPCR, Genetic testing, Personalized medicine, Anti-transglutaminase antibodies, HIV, Cancer, HRM, Neoplasm, Mutation, Overalls, Cystic fibrosis, Vaccine, Pharmaceutical industry, Software

The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Resolution Melting Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Application (Mutation Scanning, Zygosity Testing), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030
    Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.
  • Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach.
  • The drug kalydeco was approved for patients reported to have a specific genetic mutation known as "G551D mutation.

The CHOICE Institute at the University of Washington Partners With Komodo Health To Drive Critical Health Economic and Outcomes Research

Retrieved on: 
Monday, December 11, 2023
Diabetes, Health Technology, Data Management, Technology, University, Education, General Health, Professional Services, Mental Health, Infectious Diseases, Hospitals, Venture Capital, Artificial Intelligence, Software, Data Analytics, Health, Komodo, Sentinel, Drug development, Hepatitis C, Research, The, Health policy, Entrepreneurship, Sickle cell disease, Pain management, Mortality, Patient, Dementia, Cognition, Ageing, Cystic fibrosis, Doctor of Philosophy, CHOICE, Nursing, Pharmaceutical industry, Pharmacy, Economics, Policy

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy is joining forces with Komodo Health as its data and technology partner to drive comparative outcomes and cost-effectiveness research and analytics.

Key Points: 
  • The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy is joining forces with Komodo Health as its data and technology partner to drive comparative outcomes and cost-effectiveness research and analytics.
  • The CHOICE Institute envisions using Komodo’s technology to unlock high-quality insights into healthcare utilization, costs, and outcomes in the United States, working toward its vision of generating knowledge to improve individual and population health.
  • Komodo Health is the technology partner of choice for academic researchers of health economics and outcomes research (HEOR) and expediting the production of critical research-grade evidence using the most comprehensive and representative data available.
  • Academic institutions continue to be the bedrock of healthcare research, driving innovative HEOR that impacts drug development, market access, and, ultimately, patient outcomes.

Vertex Appoints Nancy Thornberry to its Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Genetics, Health, Biometrics, New York Genome Center, Chemistry, Senior, Therapy, Sickle cell disease, Biology, GV (company), Patient, Obesity, VRTX, Diabetes, DPP-4, Muhlenberg College, Merck & Co., Cystic fibrosis, Vertex Pharmaceuticals, Pharmaceutical industry, Endocrinology, Science, Vertex, Merck

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.
  • She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development.
  • “Scientific innovation is a core Vertex value and Nancy brings to our Board deep scientific expertise and a remarkable track record of discovering and developing groundbreaking medicines.
  • And today, they are on the cusp of transforming the treatment of multiple additional serious diseases,” said Nancy Thornberry.

Digital Health Strategies Closes Series A Funding Round to Expand Its Share of Health™ Patient Loyalty Platform

Retrieved on: 
Monday, December 4, 2023
Software, General Health, Professional Services, Fintech, Data Management, Technology, Health Technology, Health Insurance, Data Analytics, Insurance, Finance, Health, Keck Hospital of USC, GS, Research, NYSE, Senior, Entrepreneurship, THC, Cystic fibrosis, Tenet Healthcare, Biotechnology, The Wall Street Journal, Optum, General Atlantic, Patient, Former, Providence Health & Services, Hackensack Meridian Health, Goldman Sachs, Heart, Digital, Social determinants of health, CVS Caremark, DHS, Cystic Fibrosis Foundation, Management, Citigroup

Digital Health Strategies, Inc. (DHS), a healthcare-exclusive, data and technology-enabled solutions company, today announced it has closed a Series A funding round to expand its Share of Health™ patient loyalty platform.

Key Points: 
  • Digital Health Strategies, Inc. (DHS), a healthcare-exclusive, data and technology-enabled solutions company, today announced it has closed a Series A funding round to expand its Share of Health™ patient loyalty platform.
  • The company’s clients include some of the largest health systems in the country including Geisinger, Hackensack Meridian Health and Providence Health.
  • With the support of the country's most respected healthcare leaders, DHS is poised to supercharge the next phase of the company’s growth.
  • “Cultivating patient loyalty is imperative as health systems have increasingly grown to own more of the continuum of care,” said Ben Texter, co-founder and co-CEO of DHS.

Advisor Andrea Freiman joins UBS Private Wealth Management in Miami

Retrieved on: 
Monday, December 4, 2023
Professional Services, Finance, Consulting, Asset Management, Banking, Personal Finance, UBS, Wealth, Cystic fibrosis, University, Multimedia, Coral Gables, Florida, Certified Financial Planner, Cystic Fibrosis Foundation, Financial services, Science, Economics

UBS Private Wealth Management today announced that Andrea Freiman, CFP®, has joined the firm as a Financial Advisor in South Florida.

Key Points: 
  • UBS Private Wealth Management today announced that Andrea Freiman, CFP®, has joined the firm as a Financial Advisor in South Florida.
  • She joins the UBS Miami Private Wealth Management market, led by Brad Rosenberg, and will be located in the Coral Gables office.
  • This Private Wealth team joined UBS in early 2021 from J.P. Morgan Private Bank and has successfully grown their practice to oversee more than $6 billion in client assets.
  • “On behalf of UBS, we’re excited to welcome Andrea to the firm,” said Brad Rosenberg, Miami Market Director at UBS Private Wealth Management.

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

Retrieved on: 
Monday, November 27, 2023
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Food, Therapy, Liver, Disease, Information Holdings Inc., Vaccine, ARCT, Arcturus Therapeutics, RNA, Drug, Infection, Cystic fibrosis, Pharmaceutical industry, Arcturus

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s product candidate ARCT-032 to treat cystic fibrosis (CF).

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s product candidate ARCT-032 to treat cystic fibrosis (CF).
  • The FDA’s Office of Orphan Products Development grants orphan status to drugs being developed to treat, prevent, or diagnose a rare disease or condition affecting fewer than 200,000 people in the United States.
  • “Orphan Drug Designation is a very important regulatory milestone in our development plan for ARCT-032,” said Joseph Payne, President, and Chief Executive Officer of Arcturus Therapeutics.
  • "We are executing diligently to accelerate ARCT-032 as a potential new treatment option for people with cystic fibrosis.”
    The first CF patient in our Phase 1b study successfully completed two administrations of ARCT-032.

Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations

Retrieved on: 
Friday, November 24, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, European Medicines Agency, Type, European Commission, Vertex Pharmaceuticals, EMA, Civil service commission, CHMP, Committee, VRTX, CFTR, Mutation, Medication, Cystic fibrosis, Vaccine, Medical imaging

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor.

Key Points: 
  • Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor.
  • Data to support this submission includes the results of a Phase 3, randomized, placebo-controlled clinical study in people with rare non-F508del KAFTRIO®-responsive CFTR mutations.
  • The medicine was generally well tolerated, with safety data generally consistent with the established safety profile of KAFTRIO® in combination with ivacaftor.
  • The company also plans to submit a subset of these mutations, including N1303K and non-canonical splice mutations, not currently included in the U.S. TRIKAFTA® label to the U.S. FDA.

1910 Genetics Appoints Bridget Cole to Chief Scientific Officer

Retrieved on: 
Thursday, November 16, 2023
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Genetics, Science, Biotechnology, Other Science, Health, Drug development, Medicinal chemistry, Associate, Pfizer, Therapy, Cole, Boston College, Multimedia, Patient, Neurogenic inflammation, Doctor of Philosophy, Boston University, OpenAI, Drug discovery, Partnership, Chronic cough, AI, Playground Global, Brandeis University, SVP, Genentech, Cystic fibrosis, Pharmaceutical industry, Chemistry

1910 Genetics , the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer.

Key Points: 
  • 1910 Genetics , the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231116571874/en/
    Bridget Cole, Chief Scientific Officer at 1910 Genetics (Photo: Business Wire)
    Cole has over 25 years of drug discovery and clinical development experience, helping advance compounds from lead identification through late-stage clinical trials across a wide range of therapeutic areas.
  • I have never met anyone like Jen Nwankwo, and I love working with her and my 1910 colleagues to develop innovative solutions to merge technology with empirical biology to drive drug discovery programs,” said Bridget Cole.
  • 1910 is currently one of the only biotech companies using Microsoft’s Azure Quantum Elements to bring quantum computing power to scientific discovery.

ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Oncology, General Health, Health, COVID-19, Medical Devices, Infectious Diseases, Other Health, Jim Crockett, UBS, Bank, Cystic fibrosis, J. P. Morgan, National Council, Sepsis, Morgan Stanley, Medtech, Sepsis Alliance, Research, NASD, Adviser, University, Infection, First Republic, Family, Knowledge, Wells Fargo, RBC, Cryptocurrency

ExThera Medical Corporation is pleased to announce Erin Borger has assumed the role of CEO of ExThera.

Key Points: 
  • ExThera Medical Corporation is pleased to announce Erin Borger has assumed the role of CEO of ExThera.
  • Robert Ward, Chairman, President, and Founder will continue in those roles while focusing on Research, Product Development/IP and Manufacturing Scale Up.
  • Erin most recently held the role of Managing Director and Director of Strategic Growth at UBS Financial Services Inc .
  • He recently sat on the Board of Directors for the stem cell company Longeveron (NASD: LGVN) and is currently a Board Member of the Sepsis Alliance, the Applebaum Foundation, and ExThera Medical.

European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Medicine, European Commission, MHRA, Disease, Civil service commission, Patient, European, Medical Affairs Bureau, NHS, VRTX, CFTR, Mutation, News, Vertex Pharmaceuticals, Critical Care Medicine (journal), Cystic fibrosis, Pharmaceutical industry, Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • “As CF starts in early childhood and is a progressive disease, it is important to treat people with CF as early as possible.
  • Mall, M.D., Head of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité Universitätsmedizin Berlin.
  • Vertex will continue to work with reimbursement authorities across the European Union to ensure access for all eligible patients.